METHOD FOR SCREENING OF PATIENT TO BE ADMINISTERED WITH PHARMACEUTICAL AGENT COMPRISING ANTI-CANCER ANTIBODY AS ACTIVE INGREDIENT
    1.
    发明申请
    METHOD FOR SCREENING OF PATIENT TO BE ADMINISTERED WITH PHARMACEUTICAL AGENT COMPRISING ANTI-CANCER ANTIBODY AS ACTIVE INGREDIENT 有权
    用作为活性成分包含抗癌抗体的药物代理进行筛选的患者筛选方法

    公开(公告)号:US20100189724A1

    公开(公告)日:2010-07-29

    申请号:US12666716

    申请日:2008-06-26

    摘要: The present invention provides a method for screening a patient to be administered with a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient, said method comprising collecting samples from patients who expresses an antigen which is recognized by the anti-cancer antibody, measuring cadherin function in the samples, and selecting a patient whose the cadherin function is decreased or deleted; a method for screening a patient who has a high efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient; and a method for improving an efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient.

    摘要翻译: 本发明提供一种用于筛选待给药的患者的方法,所述药物组合物包含抗癌抗体作为活性成分,所述方法包括从表达抗原的患者中收集由抗癌抗体识别的抗原的样品, 测定样品中的钙粘蛋白功能,选择其钙粘蛋白功能减少或缺失的患者; 一种用于筛选具有高效率比的药物组合物的方法,所述药物组合物包含抗癌抗体作为活性成分; 以及提高作为有效成分的抗癌抗体的药物组合物的功效比的方法。

    Method for screening of patient to be administered with pharmaceutical agent comprising anti-cancer antibody as active ingredient
    2.
    发明授权
    Method for screening of patient to be administered with pharmaceutical agent comprising anti-cancer antibody as active ingredient 有权
    用于筛选给予包含抗癌抗体作为活性成分的药剂的患者的方法

    公开(公告)号:US08642032B2

    公开(公告)日:2014-02-04

    申请号:US12666716

    申请日:2008-06-26

    摘要: The present invention provides a method for screening a patient to be administered with a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient, said method comprising collecting samples from patients who expresses an antigen which is recognized by the anti-cancer antibody, measuring cadherin function in the samples, and selecting a patient whose the cadherin function is decreased or deleted; a method for screening a patient who has a high efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient; and a method for improving an efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient.

    摘要翻译: 本发明提供一种用于筛选待给药的患者的方法,所述药物组合物包含抗癌抗体作为活性成分,所述方法包括从表达抗原的患者中收集由抗癌抗体识别的抗原的样品, 测定样品中的钙粘蛋白功能,选择其钙粘蛋白功能减少或缺失的患者; 一种用于筛选具有高效率比的药物组合物的方法,所述药物组合物包含抗癌抗体作为活性成分; 以及提高作为有效成分的抗癌抗体的药物组合物的功效比的方法。

    Antibody against human insulin-like growth factor
    3.
    发明申请
    Antibody against human insulin-like growth factor 有权
    抗人类胰岛素样生长因子的抗体

    公开(公告)号:US20060165695A1

    公开(公告)日:2006-07-27

    申请号:US10513148

    申请日:2003-04-30

    摘要: For the effective treatment of diseases such as cancer in which hIGF participates, there have been desired to be developed antibodies which strongly bind to both factors hIGF-I and hIGF-II and inhibit their functions and fragments of these antibodies. The present invention provides antibodies which have the ability to specifically bind to human IGF-I and IGF-II to thereby inhibit the functions of human IGF-I and IGF-II and have binding activity with a binding constant of 5×109 M−1 or more measured with a biosensor BIACORE. In addition, the present invention provides diagnostics, preventives and remedies for an hIGF-mediated disease and a disease showing pathological progressing due to abnormally promoted hIGF production, which use said antibodies.

    摘要翻译: 为了有效治疗诸如hIGF参与的癌症的疾病,期望开发出与hIGF-1和hIGF-II两者强烈结合并抑制其功能和这些抗体片段的抗体。 本发明提供具有特异性结合人IGF-I和IGF-II从而抑制人IGF-I和IGF-II的功能并具有结合常数为5×10 9的结合活性的抗体, 或者用生物传感器BIACORE测量的更高/更高。 此外,本发明提供了hIGF介导的疾病的诊断,预防措施和补救措施以及由于异常促进的hIGF产生导致使用所述抗体的病理进展的疾病。

    Anti-PERP recombinant antibody
    4.
    发明授权
    Anti-PERP recombinant antibody 有权
    抗PERP重组抗体

    公开(公告)号:US08093362B2

    公开(公告)日:2012-01-10

    申请号:US11634209

    申请日:2006-12-06

    摘要: An antibody which binds to a polypeptide encoded by human PERP (p53 apoptosis effector related to PMP-22) gene which is considered to be related to incidence of cancer or the like is desired. The present invention provides a gene recombinant antibody which has no consensus sequence of an N-linked sugar chain in a variable region, specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by the PERP gene and binds to the extracellular region. The antibody is useful for treatment of various diseases expressing a polypeptide encoded by the PERP gene.

    摘要翻译: 需要与被认为与癌症等发生相关的人PERP(PMP-22)相关的p53凋亡效应基因编码的多肽结合的抗体。 本发明提供了在可变区中不具有N-连接糖链的共有序列的基因重组抗体,特异性地识别由PERP基因编码的多肽的细胞外区域的三维结构并结合到细胞外区域。 该抗体可用于治疗表达由PERP基因编码的多肽的各种疾病。

    Anti-perp recombinant antibody
    5.
    发明申请
    Anti-perp recombinant antibody 有权
    抗重组抗体

    公开(公告)号:US20080267953A1

    公开(公告)日:2008-10-30

    申请号:US11634209

    申请日:2006-12-06

    摘要: An antibody which binds to a polypeptide encoded by human PERP (p53 apoptosis effector related to PMP-22) gene which is considered to be related to incidence of cancer or the like is desired. The present invention provides a gene recombinant antibody which has no consensus sequence of an N-linked sugar chain in a variable region, specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by the PERP gene and binds to the extracellular region. The antibody is useful for treatment of various diseases expressing a polypeptide encoded by the PERP gene.

    摘要翻译: 需要与被认为与癌症等发生相关的人PERP(PMP-22)相关的p53凋亡效应基因编码的多肽结合的抗体。 本发明提供了在可变区中不具有N-连接糖链的共有序列的基因重组抗体,特异性地识别由PERP基因编码的多肽的细胞外区域的三维结构并结合到细胞外区域。 该抗体可用于治疗表达由PERP基因编码的多肽的各种疾病。

    Antibody against human insulin-like growth factor
    6.
    发明授权
    Antibody against human insulin-like growth factor 有权
    抗人类胰岛素样生长因子的抗体

    公开(公告)号:US07438911B2

    公开(公告)日:2008-10-21

    申请号:US10513148

    申请日:2003-04-30

    摘要: For the effective treatment of diseases such as cancer in which hIGF participates, there have been desired to be developed antibodies which strongly bind to both factors hIGF-I and hIGF-II and inhibit their functions and fragments of these antibodies. The present invention provides antibodies which have the ability to specifically bind to human IGF-I and IGF-II to thereby inhibit the functions of human IGF-I and IGF-II and have binding activity with a binding constant of 5×109 M−1 or more measured with a biosensor BIACORE. In addition, the present invention provides diagnostics, preventives and remedies for an hIGF-mediated disease and a disease showing pathological progressing due to abnormally promoted hIGF production, which use said antibodies.

    摘要翻译: 为了有效治疗诸如hIGF参与的癌症的疾病,期望开发出与hIGF-1和hIGF-II两者强烈结合并抑制其功能和这些抗体片段的抗体。 本发明提供具有特异性结合人IGF-I和IGF-II从而抑制人IGF-I和IGF-II的功能并具有结合常数为5×10 9的结合活性的抗体, 或者用生物传感器BIACORE测量的更高/更高。 此外,本发明提供了hIGF介导的疾病的诊断,预防措施和补救措施以及由于异常促进的hIGF产生导致使用所述抗体的病理进展的疾病。

    Camera stand with camera charging mechanism
    7.
    发明授权
    Camera stand with camera charging mechanism 有权
    相机支架带相机充电机构

    公开(公告)号:US07626634B2

    公开(公告)日:2009-12-01

    申请号:US10922277

    申请日:2004-08-19

    IPC分类号: H04N5/225

    摘要: A camera stand comprising a foot that will be placed a surface, a support having opposite ends at one of which the support is supported rotatably on the foot and turnable between a lying position and an upstanding position, an arm mechanism capable of attaching a digital camera removably at one end thereto and supported rotatably at the other end to the other end of the support such that in use the arm mechanism is adjusted in angle to the support so as to allow the camera to pick up an image of a picture/document placed under the camera while in non-use the arm mechanism is received within the confine of the support, which is then folded on the foot.

    摘要翻译: 一种相机支架,包括将被放置在表面上的脚,支撑件具有相对的端部,其中一个支撑件可旋转地支撑在脚上,并且可在平躺位置和直立位置之间转动;臂机构,其能够附接数字照相机 可拆卸地在一端向上并且可旋转地支撑在另一端到支撑件的另一端,使得在使用中臂臂机构被调整成与支撑件成一定角度,以便允许相机拾起放置的图片/文件的图像 在照相机下,在不使用时,臂机构被容纳在支撑件的限制内,然后将其折叠在脚上。